Literature DB >> 14501992

Control of filarial infections: not the beginning of the end, but more research is needed.

Achim Hoerauf1.   

Abstract

PURPOSE OF REVIEW: Infections with the filarial nematodes affect more than 150 million people mainly in the tropics. The very successful efforts to control filarial infections, however, have to be sustained by new tools that require long-term commitment to research. This review, focusing on reports from 2002 and 2003, highlights recent advances in research on immunology, understanding of pathogenesis and drug development in lymphatic filariasis and onchocerciasis research with potential relevance to the generation of new tools for control. RECENT
FINDINGS: Dramatic improvement has been achieved in the control of lymphatic filariasis and onchocerciasis by vector control and mass treatment with microfilaricidal drugs. Additional tools that could help in regional elimination or, ultimately, eradication of filariasis may arise from the development of new drugs or a vaccine. Research into the immune responses mediating protection or pathology has provided new insights into the pathways that lead to effector function and immunosuppression, such as T regulatory responses, as well as into genetic predispositions from the host's side, and to the identification of vaccine candidates that show protection in animal models. Recognition of the role the Wolbachia endosymbionts may play in activating the innate immune system has altered our understanding of immunopathology of filariasis and adverse reactions to microfilaricidal drugs. Wolbachia spp. have also proven to be suitable targets for the development of a long-term sterilizing or potentially macrofilaricidal drug.
SUMMARY: This review summarizes recent developments in the control of filariasis, in particular lymphatic filariasis and onchocerciasis, as well as in modern research into the immunity of filariasis and new drug development that could lead to additional tools necessary for sustained success in filariasis control.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14501992     DOI: 10.1097/00001432-200310000-00006

Source DB:  PubMed          Journal:  Curr Opin Infect Dis        ISSN: 0951-7375            Impact factor:   4.915


  6 in total

1.  The Wolbachia Symbiont: Here, There and Everywhere.

Authors:  Emilie Lefoulon; Jeremy M Foster; Alex Truchon; C K S Carlow; Barton E Slatko
Journal:  Results Probl Cell Differ       Date:  2020

2.  Mosquito transcriptome profiles and filarial worm susceptibility in Armigeres subalbatus.

Authors:  Matthew T Aliota; Jeremy F Fuchs; Thomas A Rocheleau; Amanda K Clark; Julián F Hillyer; Cheng-Chen Chen; Bruce M Christensen
Journal:  PLoS Negl Trop Dis       Date:  2010-04-20

3.  Asymmetric Wolbachia segregation during early Brugia malayi embryogenesis determines its distribution in adult host tissues.

Authors:  Frédéric Landmann; Jeremy M Foster; Barton Slatko; William Sullivan
Journal:  PLoS Negl Trop Dis       Date:  2010-07-27

4.  Assessment of microfilarial loads in the skin of onchocerciasis patients after treatment with different regimens of doxycycline plus ivermectin.

Authors:  Alexander Yaw Debrah; Sabine Mand; Yeboah Marfo-Debrekyei; John Larbi; Ohene Adjei; Achim Hoerauf
Journal:  Filaria J       Date:  2006-02-05

5.  The Wolbachia genome of Brugia malayi: endosymbiont evolution within a human pathogenic nematode.

Authors:  Jeremy Foster; Mehul Ganatra; Ibrahim Kamal; Jennifer Ware; Kira Makarova; Natalia Ivanova; Anamitra Bhattacharyya; Vinayak Kapatral; Sanjay Kumar; Janos Posfai; Tamas Vincze; Jessica Ingram; Laurie Moran; Alla Lapidus; Marina Omelchenko; Nikos Kyrpides; Elodie Ghedin; Shiliang Wang; Eugene Goltsman; Victor Joukov; Olga Ostrovskaya; Kiryl Tsukerman; Mikhail Mazur; Donald Comb; Eugene Koonin; Barton Slatko
Journal:  PLoS Biol       Date:  2005-03-29       Impact factor: 8.029

6.  Immunization of Mastomys coucha with Brugia malayi recombinant trehalose-6-phosphate phosphatase results in significant protection against homologous challenge infection.

Authors:  Susheela Kushwaha; Prashant Kumar Singh; Ajay Kumar Rana; Shailja Misra-Bhattacharya
Journal:  PLoS One       Date:  2013-08-28       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.